SCHEDULE: BlackRock Discloses Ovid Therapeutics Stake
Beneficial Ownership Filing
BlackRock, Inc. has reported a beneficial ownership of 5.8% of Ovid Therapeutics Inc. common stock as of June 30, 2026.
Summary
- BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Ovid Therapeutics Inc. common stock.
- The filing, dated June 30, 2026, shows BlackRock beneficially owns 10,822,672 shares.
- This represents 5.8% of the total outstanding common shares of Ovid Therapeutics Inc.
- BlackRock has sole voting power over 10,707,787 shares and sole dispositive power over 10,822,672 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership by an institutional investor and does not provide new operational or financial performance information.
Positives
- BlackRock, a significant institutional investor, holds a substantial stake in Ovid Therapeutics.
- The filing confirms BlackRock's active investment in the company, potentially signaling confidence.
Risks
- The filing does not contain specific risk factors related to BlackRock's investment strategy or Ovid Therapeutics' business operations.
Future Outlook
This filing is a snapshot of beneficial ownership as of a specific date and does not contain forward-looking statements or guidance from BlackRock regarding Ovid Therapeutics Inc.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are routine for large institutional investors like BlackRock, indicating their aggregate holdings in publicly traded companies. This filing confirms BlackRock's position as a significant shareholder in Ovid Therapeutics, a biotechnology company.
Stakeholder Impact
- Shareholders: The filing confirms BlackRock's significant ownership, which can influence market perception and trading dynamics.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of Power of Attorney for BlackRock, Inc. |
| 04/30/2023 | Previous Power of Attorney revoked. |
| 06/30/2026 | Date of Event Which Requires Filing of this Statement (Reporting Date). |
| 07/29/2026 | Date of Signature on Schedule 13G. |
Keywords
Ovid Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.